Literature DB >> 20740668

Low dose erythropoietin stimulates bone healing in mice.

P Garcia1, V Speidel, C Scheuer, M W Laschke, J H Holstein, T Histing, T Pohlemann, M D Menger.   

Abstract

Beyond its classical role in regulation of erythropoiesis, erythropoietin (EPO) has been shown to exert protective and regenerative actions in a variety of non-hematopoietic tissues. However, little is known about potential actions in bone regeneration. To analyze fracture healing in mice, a femoral 0.25 mm osteotomy gap was stabilized with a pin-clip technique. Animals were treated with 500 U EPO/kg bw per day or with vehicle only. After 2 and 5 weeks, fracture healing was analyzed biomechanically, radiologically and histologically. Expression of PCNA and NFκB was examined by Western blot analysis. Vascularization was analyzed by immunohistochemical staining of PECAM-1. Circulating endothelial progenitor cells were measured by flow-cytometry. Herein, we demonstrate that EPO-treatment significantly accelerates bone healing in mice. This is indicated by a significantly greater biomechanical stiffness and a higher radiological density of the periosteal callus at 2 and 5 weeks after fracture and stabilization. Histological analysis demonstrated significantly more bone and less cartilage and fibrous tissue in the periosteal callus. Endosteal vascularization was significantly increased in EPO-treated animals when compared to controls. The number of circulating endothelial progenitor cells was significantly greater in EPO-treated animals. The herein shown acceleration of healing by EPO may represent a promising novel treatment strategy for fractures with delayed healing and non-union formation.
Copyright © 2010 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20740668     DOI: 10.1002/jor.21219

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  24 in total

1.  Polycythemia is associated with bone loss and reduced osteoblast activity in mice.

Authors:  P R Oikonomidou; C Casu; Z Yang; B Crielaard; J H Shim; S Rivella; M G Vogiatzi
Journal:  Osteoporos Int       Date:  2015-12-09       Impact factor: 4.507

2.  Bone: Elucidating which cell erythropoietin targets in bone.

Authors:  Yusuke Shiozawa; Russell S Taichman
Journal:  Nat Rev Endocrinol       Date:  2015-03-10       Impact factor: 43.330

Review 3.  A comprehensive review of mouse diaphyseal femur fracture models.

Authors:  Zachary J Gunderson; Zachery R Campbell; Todd O McKinley; Roman M Natoli; Melissa A Kacena
Journal:  Injury       Date:  2020-04-18       Impact factor: 2.586

4.  Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy.

Authors:  Maxwell Modrak; Leigh Sundem; Ranjan Gupta; Michael J Zuscik; John Elfar
Journal:  J Bone Joint Surg Am       Date:  2019-03-20       Impact factor: 5.284

5.  Erythropoietin promotes bone formation through EphrinB2/EphB4 signaling.

Authors:  C Li; C Shi; J Kim; Y Chen; S Ni; L Jiang; C Zheng; D Li; J Hou; R S Taichman; H Sun
Journal:  J Dent Res       Date:  2015-01-13       Impact factor: 6.116

Review 6.  Effects of erythropoietin on the bone microenvironment.

Authors:  S J McGee; A M Havens; Y Shiozawa; Y Jung; R S Taichman
Journal:  Growth Factors       Date:  2011-11-28       Impact factor: 2.511

7.  Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone.

Authors:  Hongli Sun; Younghun Jung; Yusuke Shiozawa; Russell S Taichman; Paul H Krebsbach
Journal:  Tissue Eng Part A       Date:  2012-08-10       Impact factor: 3.845

8.  Erythropoietin enhances meniscal regeneration and prevents osteoarthritis formation in mice.

Authors:  Xiao-Ning Fu; Hui-Wu Li; Na Du; Xu Liang; Shi-Hao He; Kuang-Jin Guo; Tian-Fang Li
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

9.  Evaluation of the osteogenesis and angiogenesis effects of erythropoietin and the efficacy of deproteinized bovine bone/recombinant human erythropoietin scaffold on bone defect repair.

Authors:  Donghai Li; Liqing Deng; Xiaowei Xie; Zhouyuan Yang; Pengde Kang
Journal:  J Mater Sci Mater Med       Date:  2016-04-18       Impact factor: 3.896

10.  Conditional Deletion of Prolyl Hydroxylase Domain-Containing Protein 2 (Phd2) Gene Reveals Its Essential Role in Chondrocyte Function and Endochondral Bone Formation.

Authors:  Shaohong Cheng; Weirong Xing; Sheila Pourteymoor; Jan Schulte; Subburaman Mohan
Journal:  Endocrinology       Date:  2015-11-12       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.